Insulin-like growth factor 1 (IGF-1), IGF-1 density, and IGF-1/PSA ratio for prostate cancer detection

Urology

Volumn 54, Issue 4, 1999, Pages 603-606

  Djavan, Bob ^a   Bursa, Bernd ^a   Seitz, Christian ^a   Soeregi, Gabor ^a   Remzi, Mesut ^a   Basharkhah, Ali ^a   Wolfram, Roswitha ^a   Marberger, Michael ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN C; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOPSY; BLOOD LEVEL; CANCER DIAGNOSIS; CANCER RISK; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; TRANSRECTAL ULTRASONOGRAPHY;

AGED; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 0032820181     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00280-0     Document Type: Article

References (12)

1. Catalona WJ, Smith DS, Wolfert RL, et al: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274: 1214-1220, 1995.
2. Partin AW, and Carter HB: The use of prostate-specific antigen and free/total prostate-specific antigen in the diagnosis of localized prostate cancer. Urol Clin North Am 23: 531-540, 1996.
3. Vashi AR, Wojno KJ, Henricks W, et al: Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology 49: 19-27, 1997.
4. Djavan B, Zlotta AR, Byttebier G, et al: Prostate specific antigen density of the transition zone for early detection of prostate cancer. J Urol 160: 411-419, 1998.
5. Iwamura M, Sluss PM, Casamento JB, et al: Insulin like growth factor 1: action and receptor characterization in human prostate cancer cell lines. Prostate 22: 243-252, 1993.
6. Culig Z, Hobisch A, Cronauer MV, et al: Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor, keratinocyte growth factor, and epidermal growth factor. Eur Urol 27: 45-47, 1995.
7. Katz LEL, Rosenfeld RG, and Cohen P: Clinical significance of IGFBPs. Endocrinologist 5: 41-48, 1995.
8. Cohen P, Peehl DM, and Rosenfeld RG: The IGF axis in the prostate. Horm Metab Res 26: 81-84, 1994.
9. Mantzoros CS, Tzonou A, Signorello LB, et al: Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 76: 1115-1118, 1997.
10. Chan JM, Stampfer MJ, Giovannucci E, et al: Plasma insulin-like growth factor 1 and prostate cancer risk: a prospective study. Science 279: 563-566, 1998.
11. Cohen P, Graves HC, Peehl DM, et al: Prostate specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 75: 1046-1053, 1992.
12. Holly J: Insulin-like growth factor 1 and new opportunities for cancer prevention. Lancet 351: 1373-1374, 1998.